<p align="center">
  <img src="images/banner.png" alt="Trading on Trials Banner" width="100%" />
</p>

## ğŸ“˜ Introduction

After years working in biotech, I became increasingly curious about how markets respond to clinical trial results and FDA decisions. Surprisingly, **positive trial outcomes sometimes triggered stock price drops**, while **negative results occasionally caused gains**. This counterintuitive behavior inspired me to dig deeper: *Are there hidden patterns in how the market reacts to biotech press releases?*

Thanks to recent advances in **large language models (LLMs)**, it's now possible to extract nuanced insights from unstructured text at scale. This project uses LLMs to automate the parsing and annotation of ~30,000 biotech press releases from 2014â€“2025.

Each release was processed using a library of tailored prompts that extracted structured features such as:

- **Publication metadata** (date, time, timezone, title)
- **Clinical trial outcomes** (efficacy, survival rates, adverse events)
- **Narrative tone and sentiment** (e.g., bullishness, hedging, promotional language)
- **Strategic or commercial signals** (pipeline prioritization, commercial readiness, M&A potential)
- **Audience targeting and credibility cues** (investor focus, third-party validation, media presence)
- **Trial design rigor** and **regulatory framing**

These annotations were not just for descriptive analysis. I also used them to train **Random Forest classifiers** to predict post-event price movement. Specifically, I explored whether these qualitative featuresâ€”along with technical indicators like recent volatility and price momentumâ€”could help forecast:

1. **Whether a stock would significantly move in the 30 days following a press release**, and  
2. **In which direction that movement would occur**.

For example: *If a stock dropped -5% on day one after a "Positive" press release, could we predict whether it would recover?*  
By blending natural language insights with price history, the goal was to model event-driven trading opportunities in biotech using LLM-informed signals.


## ğŸ“Š Data Overview

This project analyzes **~30,000 press releases** from **~100 biotech and pharmaceutical companies** between **2014â€“2025**. 

- Press releases were collected manually from company websites as raw HTML files and parsed using scripts in `data/data_processing_scripts/`.
- Associated stock price data was sourced using the `yfinance` API.
- LLMs were used to extract structured features like date, title, and press release type.

Processed CSVs include subsets such as **positive clinical trial outcomes**, **negative outcomes**, and other categories of interest. The full dataset (~3GB) isnâ€™t included in this repo, but you can rebuild it using the provided scripts and press release files.

Want the full processed dataset? Email me at **hansenrjhan@gmail.com**.

> âš ï¸ **Note**: This dataset excludes companies that were acquired, merged, or went bankrupt â€” so extreme outcomes (like buyouts or collapses) are underrepresented.

## ğŸ§ª Methods

This project combines natural language processing and quantitative modeling to explore the market impact of biotech press releases. The workflow is as follows:

1. **LLM Prompting and Feature Extraction**  
   Using carefully designed prompts, large language models were employed to extract structured insights from each press release. This included:
   - Clinical outcome and tone
   - Strategic indicators (e.g., pipeline reprioritization, M&A hints)
   - Commercial readiness and regulatory framing
   - Audience targeting and credibility cues
   - Trial design features and real-world impact

   A total of 8 prompt templates were used to capture different angles of analysis.

2. **Feature Integration**  
   The extracted labels were compiled into structured JSON objects and merged with historical stock price features (e.g., volatility, trajectory, day-1 reaction).

3. **Modeling and Backtesting**  
   Using the combined dataset, classifiers (Random Forests) were trained to predict:
   - Whether a stock would move significantly in the 30 days following a press release
   - The **direction** of the movement (positive or negative)
   
   These models were then tested using simulated event-based backtests to evaluate performance in realistic trading scenarios.

![Methods Diagram](images/methods.png)

## ğŸ“ˆ Results

### ğŸ“° Press Release Categories and Volatility

Press releases were grouped into 9 major categories such as:

- Clinical Trial / Regulatory Updates
- Stock Offerings / Index Inclusions
- Partnerships / Collaborations
- Executive Changes
- Legal Disputes

### ğŸ“ˆ Volatility by Press Release Type

To understand which types of announcements drive the biggest market reactions, I calculated the **1-day stock price change** following each press release. The change is measured relative to the average of the **two days before the event**, which helps account for announcements released outside of trading hours.

Among all press release types:

- **Stock Offering / Index Inclusion** and **Clinical Trial / Regulatory Updates** exhibited the **highest volatility**, with large swings in both directions.
- **Partnerships and Licensing Agreements** also showed significant movement, suggesting investors pay close attention to these strategic events.
- In contrast, more routine updates such as **executive changes**, **financials**, **conferences**, and **legal disputes** produced more muted market responses.

ğŸ“‹ *Sample Summary (sorted by volatility):*

| Type                                              | Std Dev | Mean    | Median  | Min     | Max     | Count |
|---------------------------------------------------|---------|---------|---------|---------|---------|--------|
| Stock Offerings / Index Inclusion                 | 0.163   | 1.75%   | -0.14%  | -67.3%  | +306.6% | 2402   |
| Clinical Trial / Regulatory Update                | 0.148   | 0.68%   | -0.03%  | -84.9%  | +342.4% | 7247   |
| Partnership / Collaboration / Licensing Agreement | 0.131   | 1.77%   | 0.30%   | -61.7%  | +192.9% | 1306   |
| Financial Update (Quarterly or Annual)            | 0.103   | 0.30%   | -0.18%  | -71.6%  | +263.3% | 4276   |
| Executive / Board Changes                         | 0.073   | -0.14%  | -0.58%  | -31.0%  | +84.8%  | 1196   |
| Other                                             | 0.072   | 0.66%   | 0.06%   | -68.2%  | +97.9%  | 3017   |
| Company Conference Participation                  | 0.070   | 0.56%   | 0.17%   | -65.6%  | +117.1% | 4777   |
| Legal Dispute                                     | 0.062   | 1.80%   | 0.71%   | -6.5%   | +31.5%  | 90     |


### ğŸ”„ Market Reactions to Clinical Trial Outcomes

We used LLMs to categorize trial-related press releases as:

- **Positive**
- **Negative**
- **Mixed**
- **Null**

Surprisingly, nearly half of the positive outcomes triggered negative price reactionsâ€”a counterintuitive pattern that originally sparked my curiosity and inspired this project. 

| Result | Mean Return | Positive Count | Negative Count | Pos/Neg Ratio |
|--------|-------------|----------------|----------------|-------|
| Positive | +1.6% | 1583 | 1413 | 1.12 |
| Mixed    | -7.8% | 35   | 39   | 0.89 |
| Negative | -12.0% | 25   | 70   | 0.36 |

ğŸ“Š *Figure 1 â€” Price change distribution by result type:*

![Distribution of Price Change by Event Type](images/result_type_distribution.png)

### ğŸ” Deeper Insights: What Drives Market Reactions to Positive Trial Results?

While the previous section showed that **positive clinical trial results** often lead to surprisingly mixed stock price reactions, this raises a key question: *What factors influence whether the market reacts positively or negatively to seemingly good news?* To explore this, I analyzed a range of contextual featuresâ€”such as market cap, timing of the announcement, regulatory involvement, trial characteristics, and therapeutic focusâ€”to see if any patterns emerged that might help explain these divergent outcomes.

The following table summarizes the **mean return**, **sample size**, and **positive-to-negative ratio** of press releases explicitly labeled as â€œPositive Results,â€ broken down by category.

Several noteworthy patterns emerged:

- **Market Cap Matters**  
  Mid- and large-cap companies had higher positive-to-negative ratios (1.33 and 1.25, respectively), suggesting that **investors are more likely to reward positive results from larger, more established firms**. In contrast, small caps often saw negative responses, with a ratio below 1.0.

- **Timing is Telling**  
  Press releases that pointed to **future milestones** or results (e.g., upcoming presentations or planned regulatory submissions) were more likely to generate positive sentiment than those reporting current outcomes. This may reflect the market's tendency to price in **forward-looking optimism**.

- **Regulatory Context**  
  News tied to **Emergency Use Authorizations (EUA)** and **Supplemental NDAs** generated the strongest positive bias, with ratios of 1.50 and 1.36 respectively. Meanwhile, other categories like **Regulatory Opinions** or **Label Expansions** showed much more mixed reactions.

- **Trial Design Nuances**  
  Trials involving **combination therapies** slightly outperformed monotherapies in terms of market optimism. Higher trial phases (like **Phase 3**) also correlated with better returns, likely due to the perceived de-risking of results.

- **Partnership Signals**  
  Announcements involving a **partnership or co-sponsor** actually received **slightly more favorable market responses** than independent ones. This may reflect investor confidence in external validation, shared development risk, or the credibility added by collaboration with larger or more experienced partners.

- **Therapeutic Area Sensitivity**  
  Diseases affecting the **nervous system**, **respiratory system**, and **skin** were associated with stronger market reactions than areas like **urogenital** or **infectious diseases**, which actually trended negativelyâ€”even after â€œpositiveâ€ trial outcomes.

- **Drug Modality Differences**  
  While **small molecules**, **biologics**, and **gene therapies** tended to have favorable market reactions, others like **vaccines**, **peptides**, and **oligonucleotides** were more mixedâ€”suggesting that the market may still be cautious about less-established or more experimental modalities.

Together, these results highlight that a "positive" clinical trial result isn't always enough on its own to move a stock higher. The **context**â€”who's announcing, what the disease is, how the trial was structured, and what regulatory pathway is involvedâ€”plays a crucial role in shaping investor sentiment.


### ğŸ“Š Summary of Event Impact by Category

| Category                  | Subgroup / Type                         | Mean Return | Count | Pos/Neg Ratio |
|---------------------------|------------------------------------------|-------------|--------|----------------|
| **Market Cap**            | Small Cap                                | 0.013       | 923    | 0.857          |
|                           | Mid Cap                                  | 0.048       | 561    | 1.328          |
|                           | Large Cap                                | 0.008       | 1504   | 1.248          |
| **Timing**                | Future-Looking Release                   | 0.019       | 155    | 1.153          |
|                           | Present-Focused Release                  | 0.017       | 2839   | 1.122          |
| **Regulatory Body**       | FDA                                      | 0.027       | 1242   | 1.206          |
|                           | EMA                                      | -0.008      | 65     | 0.857          |
|                           | Other                                    | 0.030       | 29     | 0.813          |
| **Regulatory Action Type**| Emergency Use Authorization (EUA)        | 0.007       | 25     | 1.500          |
|                           | Supplemental NDA (sNDA)                  | 0.015       | 78     | 1.364          |
|                           | Fast Track / Orphan / Priority           | 0.010       | 94     | 1.238          |
|                           | New Drug Application (NDA)               | 0.055       | 331    | 1.135          |
|                           | Label Expansion                          | -0.006      | 41     | 1.050          |
|                           | IND Application                          | 0.015       | 24     | 1.000          |
|                           | Biologics License App (BLA)              | 0.009       | 22     | 1.000          |
|                           | Regulatory Opinion Only                  | 0.021       | 93     | 0.938          |
| **Trial Type**            | Combination Therapy                      | 0.015       | 810    | 1.189          |
|                           | Monotherapy                              | 0.018       | 2175   | 1.101          |
| **Trial Phase**           | Phase 3                                  | 0.019       | 1417   | 1.167          |
|                           | Phase 2                                  | 0.011       | 909    | 1.134          |
|                           | Phase 1                                  | 0.007       | 528    | 0.899          |
| **Partnership Type**      | Partnership                              | 0.005       | 1101   | 1.211          |
|                           | Independent                              | 0.023       | 1797   | 1.087          |
| **Therapeutic Area**      | Nervous System Diseases                  | 0.030       | 449    | 1.339          |
|                           | Respiratory Tract Diseases               | 0.030       | 133    | 1.293          |
|                           | Skin Diseases                            | 0.017       | 192    | 1.286          |
|                           | Hematology                               | 0.014       | 575    | 1.203          |
|                           | Inflammation & Immunology                | 0.021       | 448    | 1.175          |
|                           | Oncology                                 | 0.008       | 1047   | 1.128          |
|                           | Rare Genetic Diseases                    | 0.021       | 498    | 1.119          |
|                           | Cardiovascular & Metabolic Diseases      | 0.026       | 426    | 1.029          |
|                           | Infectious Diseases                      | 0.023       | 295    | 0.855          |
|                           | Urogenital Diseases                      | -0.006      | 34     | 0.619          |
| **Drug Modality**         | Small Molecule                           | 0.018       | 1348   | 1.150          |
|                           | Gene Therapy                             | 0.005       | 226    | 1.194          |
|                           | Biologic                                 | 0.016       | 1423   | 1.146          |
|                           | Oligonucleotide                          | 0.005       | 115    | 0.983          |
|                           | Peptide                                  | 0.034       | 90     | 0.957          |
|                           | Vaccine                                  | 0.018       | 119    | 0.919          |

Market capitalization was classified using a simple rule-based function: companies with a market cap under $2B were labeled **Small Cap**, those between $2B and $10B as **Mid Cap**, and those above $10B as **Large Cap**.

## ğŸ’¡ Heuristic Strategy Testing

We explored whether basic trading rules could exploit these patterns. For example:

> â€œDo positive results with a Day 1 price drop of >5% tend to bounce back in the next 30 days?â€

We simulated a few of these strategies and compared them against an S&P 500 benchmark.

ğŸ“‰ *Figure 2 â€” Strategy performance over time:*

![Comparing Heuristic Trading Strategies](images/comparing_heuristic_strategies.png)


## ğŸš§ Future Directions

I'm no longer actively working on this project, but here are ideas if you want to build on it:

- **RSS Integration:** Automate live press release tracking from company IR feeds
- **Explore Other Release Types:** Partnerships & offerings had high volatility too
- **Apply Beyond Biotech:** Framework could be adapted for sectors like medtech, fintech, etc.


## ğŸ“¬ Contact

Want the data or curious to build on this?  
Reach out: **hansenrjhan@gmail.com**


